Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents.
This study reports that a selective COX-2 inhibitor JTE-522inhibits both in vitro and in vivo growth of human lung cancer cells as a single agent. Furthermore, the adjunct use of JTE-522 is shown to significantly enhance treatment efficacy of conventional anticancer drugs not only in vitro but also in vivo without causing any noticeable side effects. Indeed, IC(50)s of various anticancer agents in vitro were reduced by up to 70%, whereas the combination therapy of JTE-522 with docetaxel and vinorelbine inhibited tumor growth in vivo by 65 and 55%, respectively. Taken together, these findings suggest that the use of a selective COX-2 inhibitor in the treatment of lung cancer may be promising, especially because of its enhancement of the treatment efficacy of conventional anticancer agents without compromising quality of life.
Hida
Toyoaki
T
Department of Internal Medicine, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan. 107974@aichi-cc.jp
Kozaki
Ken-Ichi
K
Ito
Hidemi
H
Miyaishi
Osamu
O
Tatematsu
Yoshio
Y
Suzuki
Takeshi
T
Matsuo
Keitaro
K
Sugiura
Takahiko
T
Ogawa
Makoto
M
Takahashi
Toshitada
T
Takahashi
Takashi
T
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008565:Membrane Proteins; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010080:Oxazoles / Q000627:therapeutic use*; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011451:Prostaglandin-Endoperoxide Synthases; D043823:Taxoids; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000096926:Benzenesulfonamides
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D001557:Benzenesulfonates; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D000077143:Docetaxel; D007527:Isoenzymes; D008565:Membrane Proteins; D010080:Oxazoles; D017239:Paclitaxel; D011451:Prostaglandin-Endoperoxide Synthases; D043823:Taxoids; D014747:Vinblastine; D000077235:Vinorelbine; C110453:4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; D000096926:Benzenesulfonamides; C055866:amrubicin; C496540:PTGS2 protein, human